This GLP-1 medication was originally developed to treat type 2 diabetes because it targets hormones in the brain that control hunger and metabolism
There is emerging evidence that GLP-1 receptor agonists may help reduce autoimmune inflammation, including in conditions like rheumatoid arthritis and lupus, although more studies are needed
Parameters were recorded including age, gender, weight, height, waist circumference (WC), hip circumference (HC), and waist-to-hip ratio (WHR)
OBES SURG 34 , 13241332 (2024)
it indicates that, as of the current authorised safety profile, there is insufficient evidence to include these outcomes as expected adverse drug reactions with estimable frequency
STEP 4 41 was a 68week withdrawal trial, designed to assess the effect on weight change of continuing versus discontinuing onceweekly subcutaneous semaglutide 2.4 mg after an initial 20week semaglutide runin period